Danielle Melloul

Dr. Danielle Melloul

Department of Endocrinology, Hadassah University Hospital, Jerusalem, Israel

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2008 in Biochemical Society Transactions
Verified
Journal Article
Open access
PDF file
DMDanielle Melloul
Danielle Melloul
Apoptotic β-cell death appears to be central to the pathogenesis of Type 1 diabetes mellitus and in islet graft rejection. The β-cell destruction is partially mediated by cytokines, such as IL-1β (interleukin 1β), TNFα (tumour necrosis factor α) and IFN-γ (interferon γ). IL-1β and TNFα mediate activation of the transcription factor NF-κB (nuclear factor κB) pathway. Use of a degradation-resistant NF-κB protein inhibitor (ΔNIκBα), specifically expressed in β-cells, significantly reduced IL-1β+IFN-γ-induced apoptosis. Moreover, in vivo, it protected against multiple low-dose streptozocin-induced diabetes, with reduced intra-islet lymphocytic infiltration. Thus β-cell-specific activation of NF-κB is a key event in the progressive loss of β-cells in diabetes. Inhibition of this process could be a potential effective strategy for β-cell protection.

14 January 2012 in Diabetologia
Verified
Journal Article
Closed access
PDF file
ERE. Reich
E. Reich
ATA. Tamary
A. Tamary
RSR. Vogt Sionov
R. Vogt Sionov
DMDanielle Melloul
Danielle Melloul

21 February 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RERoy Eldor
Roy Eldor
RARoy Abel
Roy Abel
DSDror Sever
Dror Sever
GSGad Sadoun
Gad Sadoun
APAmnon Peled
Amnon Peled
DMDanielle Melloul
Danielle Melloul
Pancreatic islet transplantation, a treatment for type 1 diabetes, has met significant challenges, as a substantial fraction of the islet mass fails to engraft, partly due to death by apoptosis in the peri- and post-transplantation periods. Previous evidence has suggested that NF-κB activation is involved in cytokine-mediated β-cell apoptosis and regulates the expression of pro-inflammatory and chemokine genes. We therefore sought to explore the effects of β-cell-specific inhibition of NF-κB activation as a means of cytoprotection in an allogeneic model of islet transplantation. To this end, we used islets isolated from the ToI-β transgenic mouse, where NF-κB signalling can specifically and conditionally be inhibited in β-cells by expressing an inducible and non-degradable form of IκBα regulated by the tet-on system. Our results show that β-cell-specific blockade of NF-κB led to a prolonged islet graft survival, with a relative higher preservation of the engrafted endocrine tissue and reduced inflammation. Importantly, a longer delay in allograft rejection was achieved when mice were systemically treated with the proteasome inhibitor, Bortezomib. Our findings emphasize the contribution of NF-κB activation in the allograft rejection process, and suggest an involvement of the CXCL10/IP-10 chemokine. Furthermore, we suggest a potential, readily available therapeutic agent that may temper this process.

10 January 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
LALivnat Amior
Livnat Amior
RSRohit Srivastava
Rohit Srivastava
RNRita Nano
Rita Nano
FBFederico Bertuzzi
Federico Bertuzzi
DMDanielle Melloul
Danielle Melloul
Elevated levels of lipids, in particular saturated fatty acids, are known to be associated with type 2 diabetes (T2D) and to have a negative effect on β‐cell function and survival. We bring new evidence indicating that palmitate up‐regulates cyclooxygenase‐2 (COX‐2) expression levels in human islets and in MIN6 β cells, and that it is elevated in islets isolated from T2D donors. Both small interfering specific cyclooxygenase‐2 small interfering RNA (siRNA) or the COX‐2 inhibitor celecoxib significantly inhibited apoptosis induced by palmitate. Prostaglandin E 2 (PGE 2 ), the predominant product of COX‐2 enzymatic activity, activates membrane receptors, which are members of the GPCR‐family (EP1‐EP4). In the present study, elevated expression of the PGE 2 receptor subtype 3 (EP3) receptor was observed in β cells exposed to palmitate and in islets from individuals with T2D. Down‐regulation of the pathway using EP3 siRNA or the specific L‐798, 106 antagonist markedly decreased the levels of palmitate‐induced apoptosis. Altogether, our data put forward the COX‐2‐PGE 2 ‐EP3 pathway as one of the mediators of palmitate‐induced apoptosis in β‐cells.—Amior, L., Srivastava, R., Nano, R., Bertuzzi, F., Melloul, D. The role of Cox‐2 and prostaglandin E 2 receptor EP3 in pancreatic β‐cell death. FASEB J. 33, 4975–4986 (2019). www.fasebj.org

30 November 2010 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
DSDror Sever
Dror Sever
RERoy Eldor
Roy Eldor
GSGadi Sadoun
Gadi Sadoun
LALivnat Amior
Livnat Amior
DDDaniele Dubois
Daniele Dubois
DMDanielle Melloul
Danielle Melloul
Insulin‐producing pancreatic β cells are functionally impaired or destroyed in diabetes mellitus. The onset of type 1 diabetes (T1D) represents the culmination of a prolonged prediabetic phase of immune‐mediated β‐cell destruction. To assess the in vivo metabolic status of these cells, we used the ATP‐sensitive firefly luciferase bioluminescence imaging approach, as a noninvasive probe to monitor pathological alterations in β‐cell function in the nonobese‐diabetic (NOD) mouse model of T1D. Hence, we generated the Tolβ‐NOD transgenic mice in which doxycycline‐induc‐ible luciferase gene is selectively expressed in β cells. A sharp reduction in bioluminescence emitted in vivo from β cells at the early stages, preceded by several weeks of a limited reduction in β‐cell mass. Since this decline could be due to the ongoing inflammatory process occurring in vivo , we exposed control islets to inflammatory cytokines and observed a dramatic decrease in luciferase luminescence, which appears to be due in part to a decrease in protein levels and a drop in intracellular ATP levels. This is the first evidence that selective expression of the luciferase gene represents a sensitive method for noninvasive in vivo monitoring of early β‐cell dysfunction, subtle metabolic changes, such as endogenous ATP levels, indicative of a pathological condition in a tissue at the cellular level.—Sever, D., Eldor, R., Sadoun, G., Amior, L., Dubois, D., Boitard, C., Aflalo, C., Melloul, D. Evaluation of impaired β‐cell function in nonobese‐diabetic (NOD) mouse model using bioluminescence imaging. FASEB J. 25, 676–684 (2011). www.fasebj.org

1 January 2002 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
DMDanielle Melloul
Danielle Melloul
ATAvishai M Tsur
Avishai M Tsur
DZD. Zangen
D. Zangen
Insulin is expressed exclusively in the adult beta-cells of the islets of Langerhans. Pancreatic Duodenum Homeobox-1 (PDX-1) is a major regulator of transcription in these cells. It transactivates the insulin gene by binding to a specific DNA motif in its promoter region. Glucose, the main physiological regulator of insulin secretion, also regulates insulin gene transcription through PDX-1. While acute exposure to high glucose concentrations causes an increase in PDX-1 binding, and consequently in insulin mRNA levels, chronic hyperglycemia (toxic to the beta-cell) leads to a decrease in PDX-1 and insulin levels. PDX-1 is absolutely required for pancreas development. In view of the selective expression in adult beta-cells, pancreatic agenesis in both the pdx-1 null mouse and a human carrying a homozygous mutation of PDX-1 was an unexpected and remarkable finding. The homozygous clinical phenotype was neonatal diabetes mellitus (DM) and exocrine insufficiency. Heterozygosity for PDX-1 mutations was found in some individuals with a newly characterized subtype of maturity-onset diabetes of the young (MODY4) and in others with type 2 DM. This review underlines the unique role of PDX-1 in maintaining adult beta-cell-specific functions in normal and disease-related states.